Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes?
Featuring
Professor Christiane Angermann | Germany
Professor Ricardo Carvalho | Portugal
Related content
Document ID: PC-ASK-100758
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Clinical relationship between the heart and the kidneys
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
How has recent evidence and the ESC 2023 guidelines changed management of heart failure?
Theresa McDonagh (United Kingdom)
What's new for the treatment of chronic heart failure from the ESC 2023 guidelines?
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
The heart failure patient through a holistic lens (Full)
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)